nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2014 | Original Article

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

verfasst von: S. M. Landau, B. A. Thomas, L. Thurfjell, M. Schmidt, R. Margolin, M. Mintun, M. Pontecorvo, S. L. Baker, W. J. Jagust, the Alzheimer’s Disease Neuroimaging Initiative

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The increasing use of amyloid PET in Alzheimer’s disease research and clinical trials has motivated efforts to standardize methodology. We compared retention of the ¹¹C radiotracer Pittsburgh Compound B (PiB) and that of two ¹⁸F amyloid radiotracers (florbetapir and flutemetamol) using two study populations. We also examined the feasibility of converting between tracer-specific measures, using PiB as the common link between the two ¹⁸F tracers.

Methods

One group of 40 subjects underwent PiB and flutemetamol imaging sessions and a separate group of 32 subjects underwent PiB and florbetapir imaging sessions. We compared cortical and white matter retention for each ¹⁸F tracer relative to that of PiB, as well as retention in several reference regions and image analysis methods. Correlations between tracer pairs were used to convert tracer-specific threshold values for amyloid positivity between tracers.

Results

Cortical retention for each pair of tracers was strongly correlated regardless of reference region (PiB–flutemetamol, ρ = 0.84–0.99; PiB–florbetapir, ρ = 0.83–0.97) and analysis method (ρ = 0.90–0.99). Compared to PiB, flutemetamol had higher white matter retention, while florbetapir had lower cortical retention. Two previously established independent thresholds for amyloid positivity were highly consistent when values were converted between tracer pairs.

Conclusion

Despite differing white and grey matter retention characteristics, cortical retention for each ¹⁸F tracer was highly correlated with that of PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency. Standardization of analysis methods and measurement scales may facilitate the comparison of amyloid PET data obtained using different tracers.

Nur mit Berechtigung zugänglich

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129–35. doi:10.1016/S1474-4422(08)70001-2.PubMedCrossRef

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29. doi:10.1002/ana.22068.PubMedCrossRef

Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9. doi:10.1007/s00259-012-2088-x.PubMedCrossRef

Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83(9):923–6. doi:10.1136/jnnp-2012-302548.PubMedCrossRef

Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012;53(3):415–24. doi:10.2967/jnumed.111.094029.PubMedCrossRef

Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013;54(1):70–7. doi:10.2967/jnumed.112.109009.PubMedCentralPubMedCrossRef

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913–20. doi:10.2967/jnumed.109.069088.PubMedCentralPubMedCrossRef

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456–65. doi:10.1016/j.neurobiolaging.2007.03.029.PubMedCrossRef

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25. doi:10.1212/01.wnl.0000261919.22630.ea.PubMedCrossRef

10.

Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50(2):198–204. doi:10.2967/jnumed.108.057984.PubMedCrossRef

11.

Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50(8):1251–9. doi:10.2967/jnumed.109.063305.PubMedCrossRef

12.

Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19. doi:10.1007/s00259-011-1745-9.PubMedCrossRef

13.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19. doi:10.1002/ana.20009.PubMedCrossRef

14.

Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol. 2012;69(5):623–9. doi:10.1001/archneurol.2011.2748.PubMedCentralPubMedCrossRef

15.

Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310–23. doi:10.1093/brain/awn320.PubMedCentralPubMedCrossRef

16.

Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54(8):1472–8. doi:10.2967/jnumed.112.115006.PubMedCrossRef

17.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193–9. doi:10.1212/WNL.0b013e3181bc010c.PubMedCentralPubMedCrossRef

18.

Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378–84. doi:10.2967/jnumed.111.090340.PubMedCrossRef

19.

Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669–78. doi:10.1016/S1474-4422(12)70142-4.PubMedCrossRef

20.

Landau SM, Mintun M, Joshi A, Koeppe RA, Petersen RC, Aisen P, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578–86. doi:10.1002/ana.23650.PubMedCentralPubMedCrossRef

21.

Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36(10):1629–38. doi:10.1007/s00259-009-1129-6.PubMedCentralPubMedCrossRef

Titel: Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
verfasst von: S. M. Landau
B. A. Thomas
L. Thurfjell
M. Schmidt
R. Margolin
M. Mintun
M. Pontecorvo
S. L. Baker
W. J. Jagust
the Alzheimer’s Disease Neuroimaging Initiative
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2753-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Thymidine phosphorylase influences [18F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer

Early and delayed prediction of axillary lymph node neoadjuvant response by 18F-FDG PET/CT in patients with locally advanced breast cancer

PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects

PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714